Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.36 |
| ▸ | F9 | P00740 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28796517 | 0.89 | ACHE (0.43) | SLC7A5LTA4HMEN1KMT2ASYK | |
| SCHEMBL27847543 | 0.86 | SLC7A5 (0.45) | SLC7A5LTA4HMEN1KMT2ASYK | |
| SCHEMBL855255 | 0.85 | LOXL2 (0.41) | SLC7A5LOXL2NR1H2LTA4HKMT2A | |
| SCHEMBL27559984 | 0.84 | SLC7A5 (0.43) | SLC7A5NR1H2LTA4H | |
| Ammonia Solution, Strong SCHEMBL23885016 | 0.84 | LOXL2 (0.40) | SLC7A5LOXL2NR1H2LTA4HKMT2A | |
| SCHEMBL14975818 | 0.83 | SLC7A5 (0.45) | SLC7A5LOXL2NR1H2ADRA1DENPP2 | |
| SCHEMBL13546232 | 0.83 | SLC7A5 (0.40) | SLC7A5LTA4HMEN1KMT2ASYK | |
| SCHEMBL3307226 | 0.82 | MEN1 (0.40) | SLC7A5LTA4HMEN1KMT2ASYK | |
| SCHEMBL27881041 | 0.81 | SLC7A5 (0.44) | SLC7A5LTA4HMEN1KMT2ASYK | |
| SCHEMBL7210714 | 0.81 | CPN1 (0.42) | SLC7A5NR1H2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| EP-1363874-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| EP-1368317-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-7101911-B2 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2006-09-05 | — | — | US | disclosed |
| US-7060716-B2 | Compound containing two triple bonds | ALTANA PHARMA AG (DE) | 2006-06-13 | — | — | US | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| US-20040067943-A1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1368317-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| EP-1363874-A2 | TRYPTASE INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030083344-A1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-1244643-A1 | TRYPTASE INHIBITORS | ALTANA Pharma AG (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002066420-A2 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066430-A1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-29 | — | — | WO | disclosed |
| WO-2001046168-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | SLC7A5 4107/4885LOXL2 86/4885NR1H2 10/4885 |
| US-20030083344-A1 | Tryptase inhibitors | TPSAB1, TPSB2, TPSG1 | SLC7A5 1874/4885LOXL2 1231/4885NR1H2 4185/4885 |
| US-20040067943-A1 | Tryptase inhibitors | TPSB2, TPSAB1, TPSG1 | SLC7A5 870/4885LOXL2 540/4885NR1H2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.